MetaCap

Cuprina (Cayman) (CUPR) vs CollPlant Biotechnologies (OPHI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cuprina (Cayman) is the larger company by market cap ($10.8 million vs $9.6 million), about 1.1 times the size, while CollPlant Biotechnologies is growing revenue faster (+360.4% vs +9.2%). CollPlant Biotechnologies converts more of its revenue into profit, with a net margin of -484.6% versus -9366.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CUPR-16.07%OPHI-32.54%
+2%-16%-34%
Nov 12, 20261 yearNov 20, 2026
CUPR-16.57%OPHI-14.25%
+1%-8%-17%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CUPR versus OPHI key metrics
MetricCUPROPHI
Share price$1.41$3.13
Market cap$10.79M$9.63M
1-day change-6.00%-2.49%
YTD return-55.94%—
1-year return-75.18%—
EPS (TTM)$-1.40$-9.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$38.79K$2.37M
Revenue growth (YoY)+9.20%+360.39%
Net income (latest FY)$-3.63M$-11.49M
Gross margin-1.29%64.78%
Operating margin-9680.12%-484.31%
Net margin-9366.70%-484.56%
52-week high$14.80$22.50
52-week low$1.38$2.64
Distance from 52-week high-90.47%-86.09%
Average volume115.59K385.37K
Shares outstanding5.89M3.08M
Employees10—
SectorHealth CareHealth Care
IndustryIndustrial SpecialtiesIndustrial Specialties

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CollPlant Biotechnologies is more profitable, keeping -484.6 cents of every revenue dollar as net income versus -9366.7 cents for Cuprina (Cayman).
  • CollPlant Biotechnologies grew revenue faster in its latest fiscal year (+360.39% vs +9.20%).

About Cuprina (Cayman)

CUPR stock →

Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name.

Health Care · Industrial Specialties · 10 employees

CUPR vs OPHI FAQ

Which is bigger, Cuprina (Cayman) or CollPlant Biotechnologies?

Cuprina (Cayman) (CUPR) is larger, with a market capitalization of $10.79M compared with $9.63M for CollPlant Biotechnologies (OPHI).

Are Cuprina (Cayman) and CollPlant Biotechnologies in the same industry?

Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.

More comparisons